Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis
Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J
Journal of hepatology · 389 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Health and Medical Research Council
- Subvenciones
- National Health and Medical Research Council (358398)
Según 1 financiador declarado.
Publicación
- Publicado
- 2011-10-27 · J Hepatol · vol. 56 · número 4 · págs. 944–951
- Editorial
- Elsevier BV
- Citado
- 572 citas · más que el 95% de estudios similares · 3.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 69 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Liver Disease Diagnosis and Treatment · Fatty Acid Research and Health · Alcohol Consumption and Health Effects
- Palabras clave
- omega-3 polyunsaturated fatty acids, non-alcoholic fatty liver disease, dietary supplementation, liver fat, alanine aminotransferase, aspartate aminotransferase, liver function tests, obesity, insulin resistance
- MeSH
- liver, humans, fatty liver, alanine transaminase, aspartate aminotransferases, fatty acids, omega-3, treatment outcome, dietary supplements, adult, female, male, lipid metabolism, non-alcoholic fatty liver disease
6 autores
- Helen M. Parker🇦🇺The University of Sydney
- Nathan Anthony Johnson🇦🇺The University of Sydney
- Catriona A. Burdon🇦🇺The University of Sydney
- Jeffrey S. Cohn🇦🇺The Heart Research Institute
- Helen T O'Connor🇦🇺The University of Sydney
- Jacob George🇦🇺 · autor de correspondenciaThe University of Sydney; Westmead Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Non-alcoholic fatty liver disease (NAFLD) is a frequent accompaniment of obesity and insulin resistance. With the prevalence approaching 85% in obese populations, new therapeutic approaches to manage NAFLD are warranted. A systematic search of the literature was conducted for studies pertaining to the effect of omega-3 polyunsaturated fatty acid (PUFA) supplementation on NAFLD in humans. Primary outcome measures were liver fat and liver function tests: alanine aminotransferase (ALT) and aspartate aminotransferase [1]. Data were pooled and meta-analyses conducted using a random effects model. Nine eligible studies, involving 355 individuals given either omega-3 PUFA or control treatment were included. Beneficial changes in liver fat favoured PUFA treatment (effect size=-0.97, 95% CI: -0.58 to -1.35, p<0.001). A benefit of PUFA vs. control was also observed for AST (effect size=-0.97, 95% CI: -0.13 to -1.82, p=0.02). There was a trend towards favouring PUFA treatment on ALT but this was not significant (effect size=-0.56, 95% CI: -1.16 to 0.03, p=0.06). Sub-analyses of only randomised control trials (RCTs) showed a significant benefit for PUFA vs. control on liver fat (effect size=-0.96, 95% CI: -0.43 to -1.48, p<0.001), but not for ALT (p=0.74) or AST (p=0.28). There was significant heterogeneity between studies. The pooled data suggest that omega-3 PUFA supplementation may decrease liver fat, however, the optimal dose is currently not known. Well designed RCTs which quantify the magnitude of effect of omega-3 PUFA supplementation on liver fat are needed.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.